Undermining the Gold Standard? The Role of Non-Comparative Evidence in Health Technology Assessment

August 25, 2017

Poster presented at ISPOR USA, Boston, 20-24 May, 2017

Previous Flipbook
Regulatory, Pricing and Reimbursement Landscape Of Biosimilars In Australia
Regulatory, Pricing and Reimbursement Landscape Of Biosimilars In Australia

Next Flipbook
IQWIG Versus the G-BA Frequency of Divergent Opinions in Germany and Their Impact on Global Pricing
IQWIG Versus the G-BA Frequency of Divergent Opinions in Germany and Their Impact on Global Pricing